nicotine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Devices or delivery systems used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.52 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 819.37 13.90 296 18080 24080 63446566
Nicotine dependence 580.56 13.90 110 18266 607 63470039
Drug withdrawal syndrome neonatal 287.59 13.90 75 18301 2006 63468640
Drug dependence 244.12 13.90 126 18250 24357 63446289
Foetal exposure during pregnancy 202.27 13.90 122 18254 31840 63438806
Incorrect product administration duration 196.84 13.90 86 18290 11460 63459186
Premature delivery 195.29 13.90 117 18259 30164 63440482
Product adhesion issue 191.42 13.90 66 18310 4653 63465993
Overdose 169.59 13.90 187 18189 114891 63355755
Chronic sinusitis 163.28 13.90 78 18298 12765 63457881
Paraesthesia oral 146.91 13.90 83 18293 19173 63451473
Procedural pain 127.89 13.90 79 18297 21490 63449156
Myocardial stunning 99.86 13.90 20 18356 153 63470493
Maternal exposure during pregnancy 96.53 13.90 203 18173 219859 63250787
Vaginal flatulence 92.10 13.90 35 18341 3258 63467388
Application site erythema 85.60 13.90 37 18339 4798 63465848
Rib deformity 84.85 13.90 19 18357 260 63470386
Jaundice neonatal 79.71 13.90 23 18353 902 63469744
Intentional product misuse 79.44 13.90 93 18283 60824 63409822
Application site pruritus 78.86 13.90 33 18343 3951 63466695
Dependence 76.35 13.90 27 18349 2050 63468596
Accidental overdose 75.76 13.90 59 18317 23250 63447396
Proctitis 75.15 13.90 35 18341 5406 63465240
Rhesus incompatibility 72.58 13.90 14 18362 86 63470560
Vaginal discharge 71.09 13.90 40 18336 9158 63461488
Drug abuse 69.58 13.90 95 18281 72423 63398223
Poor feeding infant 69.26 13.90 17 18359 353 63470293
Necrosis ischaemic 67.99 13.90 20 18356 840 63469806
Female genital tract fistula 64.25 13.90 35 18341 7524 63463122
Premature baby 62.06 13.90 50 18326 20685 63449961
Product quality issue 61.06 13.90 63 18313 35802 63434844
Therapeutic product effect incomplete 60.21 13.90 120 18256 124936 63345710
Radiculopathy 60.00 13.90 35 18341 8576 63462070
Tobacco abuse 57.90 13.90 17 18359 709 63469937
Pneumonia streptococcal 57.04 13.90 21 18355 1790 63468856
Chronic obstructive pulmonary disease 54.00 13.90 78 18298 62608 63408038
Oligohydramnios 52.79 13.90 29 18347 6337 63464309
Beta haemolytic streptococcal infection 51.20 13.90 20 18356 2005 63468641
Nasal obstruction 50.59 13.90 19 18357 1712 63468934
Rheumatoid arthritis 50.13 13.90 7 18369 253812 63216834
Arthropathy 50.02 13.90 5 18371 234787 63235859
Reversible airways obstruction 49.44 13.90 19 18357 1823 63468823
Exposure during pregnancy 47.84 13.90 125 18251 155422 63315224
Alopecia 46.14 13.90 20 18356 337516 63133130
Maternal exposure during breast feeding 45.64 13.90 23 18353 4218 63466428
Drug ineffective 45.06 13.90 480 17896 1044285 62426361
Throat clearing 44.43 13.90 19 18357 2400 63468246
Dyspepsia 43.22 13.90 93 18283 102103 63368543
Low birth weight baby 41.96 13.90 26 18350 7103 63463543
Joint swelling 40.84 13.90 22 18354 327644 63143002
Systemic lupus erythematosus 40.69 13.90 6 18370 208912 63261734
Exposure via breast milk 40.58 13.90 17 18359 2040 63468606
Oral candidiasis 38.71 13.90 40 18336 22758 63447888
Frequent bowel movements 38.38 13.90 40 18336 22982 63447664
Fatigue 38.17 13.90 131 18245 887897 62582749
Treatment failure 38.11 13.90 6 18370 199037 63271609
Application site rash 37.41 13.90 17 18359 2481 63468165
Congenital tricuspid valve incompetence 36.85 13.90 8 18368 94 63470552
Therapeutic product effect decreased 36.59 13.90 6 18370 193181 63277465
Application site reaction 36.37 13.90 12 18364 738 63469908
Colitis ulcerative 35.95 13.90 41 18335 26050 63444596
Contraindicated product administered 34.67 13.90 10 18366 217638 63253008
Congenital pulmonary hypertension 34.56 13.90 7 18369 57 63470589
Treatment noncompliance 34.43 13.90 48 18328 37277 63433369
Arthralgia 34.31 13.90 71 18305 569639 62901007
Drug intolerance 33.91 13.90 24 18352 308637 63162009
Chest X-ray abnormal 33.04 13.90 19 18357 4530 63466116
Substance abuse 32.07 13.90 19 18357 4788 63465858
Sputum purulent 32.01 13.90 12 18364 1075 63469571
Maternal drugs affecting foetus 30.55 13.90 19 18357 5223 63465423
Application site irritation 29.70 13.90 13 18363 1737 63468909
Developmental hip dysplasia 29.30 13.90 12 18364 1360 63469286
Secondary immunodeficiency 29.21 13.90 12 18364 1371 63469275
Caesarean section 29.13 13.90 30 18346 17002 63453644
Premature separation of placenta 28.93 13.90 13 18363 1848 63468798
Glossodynia 28.89 13.90 8 18368 178868 63291778
Toxicity to various agents 28.40 13.90 144 18232 247106 63223540
Full blood count abnormal 28.08 13.90 40 18336 31677 63438969
Abdominal discomfort 27.97 13.90 31 18345 320854 63149792
Discomfort 27.95 13.90 7 18369 167367 63303279
Agitation neonatal 27.69 13.90 9 18367 528 63470118
Reversible cerebral vasoconstriction syndrome 27.39 13.90 14 18362 2644 63468002
Anxiety 27.33 13.90 130 18246 217411 63253235
Dysmetropsia 27.08 13.90 6 18370 78 63470568
Musculoskeletal stiffness 26.73 13.90 10 18366 184608 63286038
Infection 26.25 13.90 17 18359 229156 63241490
Hepatic enzyme increased 26.05 13.90 13 18363 202315 63268331
Axonal neuropathy 25.51 13.90 10 18366 1012 63469634
Loss of proprioception 25.32 13.90 8 18368 428 63470218
Wound 25.09 13.90 8 18368 163255 63307391
Colitis 25.06 13.90 48 18328 48480 63422166
Rhinitis 25.03 13.90 23 18353 11343 63459303
Xanthogranuloma 24.93 13.90 4 18372 6 63470640
Swelling 24.66 13.90 26 18350 275352 63195294
Application site swelling 23.11 13.90 8 18368 570 63470076
Symphysiolysis 23.05 13.90 4 18372 12 63470634
Upper-airway cough syndrome 23.02 13.90 22 18354 11396 63459250
Abnormal dreams 22.61 13.90 21 18355 10495 63460151
Sneezing 22.38 13.90 27 18349 18191 63452455
Application site dermatitis 22.34 13.90 6 18370 180 63470466
Condition aggravated 21.82 13.90 53 18323 402164 63068482
Nasopharyngitis 21.66 13.90 25 18351 254232 63216414
Premature labour 21.33 13.90 22 18354 12482 63458164
Diarrhoea 21.26 13.90 121 18255 715245 62755401
Abortion induced 21.15 13.90 20 18356 10222 63460424
Irritability 21.06 13.90 35 18341 31659 63438987
Drug screen positive 20.76 13.90 13 18363 3616 63467030
Malaise 20.57 13.90 197 18179 415757 63054889
Mobility decreased 20.35 13.90 5 18371 121154 63349492
Impaired healing 19.82 13.90 3 18373 102539 63368107
Cardiac death 19.18 13.90 7 18369 582 63470064
Application site vesicles 19.10 13.90 9 18367 1426 63469220
Rectal haemorrhage 18.88 13.90 43 18333 48987 63421659
Pubic pain 18.78 13.90 5 18371 145 63470501
Antipsychotic drug level decreased 18.54 13.90 6 18370 347 63470299
False positive investigation result 18.47 13.90 7 18369 646 63470000
Respiratory failure 18.35 13.90 68 18308 101790 63368856
Suicidal ideation 17.98 13.90 49 18327 62372 63408274
Gastrointestinal disorder 17.55 13.90 8 18368 131231 63339415
Prinzmetal angina 17.41 13.90 7 18369 757 63469889
Pre-eclampsia 17.29 13.90 17 18359 9116 63461530
Blister 17.22 13.90 8 18368 129806 63340840
Application site burn 16.81 13.90 7 18369 827 63469819
Application site pain 16.74 13.90 12 18364 4170 63466476
Megacolon 16.64 13.90 9 18367 1906 63468740
Foetal distress syndrome 16.61 13.90 8 18368 1330 63469316
Application site scar 16.56 13.90 5 18371 230 63470416
Sleep disorder due to a general medical condition 16.53 13.90 19 18357 12169 63458477
Contusion 16.02 13.90 12 18364 150032 63320614
Selective eating disorder 15.98 13.90 9 18367 2063 63468583
Tobacco poisoning 15.95 13.90 4 18372 91 63470555
Withdrawal syndrome 15.93 13.90 24 18352 19973 63450673
Product use in unapproved indication 15.91 13.90 17 18359 179063 63291583
Drug abuser 15.55 13.90 10 18366 2913 63467733
Oophoritis 15.51 13.90 4 18372 102 63470544
Decreased appetite 15.30 13.90 31 18345 251021 63219625
Peripheral swelling 15.24 13.90 34 18342 265908 63204738
Nightmare 15.24 13.90 23 18353 19171 63451475
Drug detoxification 14.86 13.90 5 18371 327 63470319
Poor quality product administered 14.85 13.90 10 18366 3146 63467500
Injection site erythema 14.84 13.90 3 18373 83171 63387475
Nausea 14.81 13.90 337 18039 854134 62616512
Completed suicide 14.75 13.90 82 18294 145591 63325055
Productive cough 14.73 13.90 46 18330 63162 63407484
Expired product administered 14.58 13.90 13 18363 6168 63464478
Patent ductus arteriosus 14.33 13.90 11 18365 4239 63466407
Hepatitis C 14.27 13.90 12 18364 5262 63465384
Foetal growth restriction 14.19 13.90 14 18362 7539 63463107
Neonatal respiratory distress 14.01 13.90 5 18371 390 63470256
Plethysmography 14.00 13.90 3 18373 33 63470613

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 366.90 13.42 77 13662 541 34942651
Drug withdrawal syndrome neonatal 331.33 13.42 101 13638 3518 34939674
Drug dependence 273.86 13.42 150 13589 24067 34919125
Incorrect product administration duration 225.47 13.42 81 13658 4730 34938462
Foetal exposure during pregnancy 208.97 13.42 149 13590 37952 34905240
Intentional product misuse 147.94 13.42 131 13608 45480 34897712
Overdose 145.69 13.42 179 13560 90880 34852312
Accidental overdose 129.69 13.42 87 13652 20053 34923139
Product adhesion issue 118.54 13.42 38 13701 1562 34941630
Premature baby 105.73 13.42 76 13663 19557 34923635
Maternal exposure during breast feeding 103.59 13.42 34 13705 1507 34941685
Dependence 88.02 13.42 28 13711 1122 34942070
Jaundice neonatal 75.82 13.42 26 13713 1320 34941872
Toxicity to various agents 73.39 13.42 208 13531 200154 34743038
Low birth weight baby 73.15 13.42 43 13696 7862 34935330
Exposure via breast milk 72.72 13.42 28 13711 1982 34941210
Tobacco poisoning 65.81 13.42 11 13728 15 34943177
Alcohol abuse 64.08 13.42 33 13706 4657 34938535
Foetal disorder 62.75 13.42 20 13719 806 34942386
Tobacco abuse 60.95 13.42 17 13722 429 34942763
Poor feeding infant 57.83 13.42 17 13722 520 34942672
Neutropenia neonatal 53.11 13.42 17 13722 695 34942497
Drug screen positive 51.73 13.42 27 13712 3916 34939276
Breech presentation 50.65 13.42 12 13727 154 34943038
Tremor neonatal 48.94 13.42 14 13725 388 34942804
Drug abuser 48.82 13.42 26 13713 3928 34939264
Foetal distress syndrome 45.86 13.42 17 13722 1083 34942109
Alcohol interaction 44.19 13.42 22 13717 2891 34940301
Agitation neonatal 42.28 13.42 16 13723 1080 34942112
Finnegan score increased 38.20 13.42 7 13732 21 34943171
Drug withdrawal syndrome 34.90 13.42 41 13698 19793 34923399
Application site pruritus 34.76 13.42 15 13724 1422 34941770
Body temperature abnormal 34.29 13.42 12 13727 647 34942545
Infant irritability 34.29 13.42 7 13732 42 34943150
Substance abuse 33.14 13.42 26 13713 7615 34935577
Schizophrenia 32.33 13.42 27 13712 8639 34934553
Drug use disorder 31.59 13.42 20 13719 4171 34939021
Withdrawal syndrome 31.14 13.42 31 13708 12424 34930768
Product availability issue 30.85 13.42 15 13724 1872 34941320
Application site erythema 30.66 13.42 16 13723 2320 34940872
Drug abuse 30.58 13.42 97 13642 98999 34844193
Rhesus incompatibility 28.35 13.42 6 13733 44 34943148
Infective exacerbation of chronic obstructive airways disease 28.14 13.42 14 13725 1837 34941355
Floppy infant 27.99 13.42 7 13732 114 34943078
Treatment noncompliance 27.91 13.42 44 13695 28056 34915136
Laryngeal dysplasia 27.37 13.42 4 13735 0 34943192
Application site reaction 27.05 13.42 9 13730 416 34942776
Product quality issue 26.36 13.42 33 13706 17002 34926190
Off label use 25.86 13.42 82 13657 419442 34523750
Venolymphatic malformation 25.43 13.42 5 13734 24 34943168
Tobacco user 24.39 13.42 9 13730 566 34942626
Tachycardia 24.36 13.42 81 13658 84691 34858501
Neonatal hypoxia 23.46 13.42 8 13731 399 34942793
Regurgitation 23.34 13.42 12 13727 1687 34941505
Diarrhoea 21.44 13.42 80 13659 389832 34553360
Oropharyngeal discomfort 21.02 13.42 14 13725 3182 34940010
Application site rash 20.91 13.42 9 13730 848 34942344
Brain stem syndrome 20.90 13.42 8 13731 557 34942635
Vitamin B12 deficiency 20.31 13.42 15 13724 4016 34939176
Acne infantile 20.26 13.42 5 13734 77 34943115
Application site scar 19.74 13.42 4 13735 23 34943169
Potentiating drug interaction 19.59 13.42 16 13723 4961 34938231
Renal hypoplasia 19.27 13.42 5 13734 95 34943097
Renal impairment 18.50 13.42 7 13732 94506 34848686
Euphoric mood 17.85 13.42 16 13723 5625 34937567
Pulmonary valve stenosis congenital 17.53 13.42 5 13734 137 34943055
Agitation 17.52 13.42 56 13683 57343 34885849
Insomnia 17.49 13.42 84 13655 103823 34839369
Anxiety 17.18 13.42 81 13658 99347 34843845
Palpitations 17.04 13.42 44 13695 39942 34903250
Weight decrease neonatal 16.98 13.42 6 13733 333 34942859
Adjustment disorder with mixed anxiety and depressed mood 16.92 13.42 3 13736 7 34943185
Application site vesicles 16.73 13.42 7 13732 615 34942577
Antipsychotic drug level increased 16.43 13.42 13 13726 3852 34939340
Breathing-related sleep disorder 16.15 13.42 5 13734 183 34943009
Myocarditis 15.81 13.42 23 13716 13659 34929533
Unresponsive to stimuli 15.74 13.42 34 13705 27535 34915657
Necrotising ulcerative gingivostomatitis 15.67 13.42 4 13735 71 34943121
Emphysema 15.62 13.42 19 13720 9506 34933686
Application site urticaria 15.52 13.42 4 13735 74 34943118
Myoclonic epilepsy 15.40 13.42 8 13731 1149 34942043
Disease progression 15.34 13.42 12 13727 108065 34835127
Drug tolerance increased 15.00 13.42 6 13733 470 34942722
Nightmare 14.93 13.42 23 13716 14368 34928824
Neonatal disorder 14.79 13.42 7 13732 823 34942369
Eructation 14.15 13.42 13 13726 4718 34938474
Application site pain 14.12 13.42 9 13730 1899 34941293
Maternal drugs affecting foetus 14.06 13.42 12 13727 3953 34939239
Miosis 14.00 13.42 18 13721 9517 34933675
Hypersensitivity 13.84 13.42 54 13685 60981 34882211
Application site discolouration 13.79 13.42 5 13734 299 34942893
Maternal exposure during pregnancy 13.71 13.42 13 13726 4905 34938287
Death 13.70 13.42 96 13643 397953 34545239
Depressed mood 13.61 13.42 26 13713 19291 34923901
Non-small cell lung cancer stage IIIB 13.44 13.42 3 13736 29 34943163

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 587.33 12.74 118 24988 837 79718445
Drug dependence 462.06 12.74 235 24871 40534 79678748
Incorrect product administration duration 333.85 12.74 130 24976 11892 79707390
Overdose 258.84 12.74 304 24802 183902 79535380
Accidental overdose 209.03 12.74 139 24967 39442 79679840
Macular degeneration 157.32 12.74 75 25031 11221 79708061
Chronic sinusitis 150.09 12.74 76 25030 12950 79706332
Intentional product misuse 138.34 12.74 160 24946 95005 79624277
Paraesthesia oral 130.58 12.74 81 25025 20390 79698892
Procedural pain 112.11 12.74 77 25029 23007 79696275
Application site erythema 96.65 12.74 42 25064 5068 79714214
Toxicity to various agents 95.95 12.74 321 24785 421219 79298063
Myocardial stunning 94.80 12.74 20 25086 185 79719097
Vaginal flatulence 93.86 12.74 34 25072 2541 79716741
Application site pruritus 91.10 12.74 37 25069 3773 79715509
Drug abuse 85.45 12.74 170 24936 162521 79556761
Product adhesion issue 84.93 12.74 32 25074 2672 79716610
Rib deformity 75.58 12.74 17 25089 217 79719065
Alcohol abuse 72.82 12.74 35 25071 5328 79713954
Tobacco abuse 71.62 12.74 22 25084 984 79718298
Substance abuse 68.00 12.74 42 25064 10484 79708798
Female genital tract fistula 66.32 12.74 34 25072 5941 79713341
Vaginal discharge 64.63 12.74 36 25070 7427 79711855
Proctitis 63.95 12.74 34 25072 6398 79712884
Tobacco poisoning 63.19 12.74 13 25093 105 79719177
Dependence 63.02 12.74 25 25081 2397 79716885
Necrosis ischaemic 61.66 12.74 20 25086 1070 79718212
Drug abuser 60.39 12.74 32 25074 5981 79713301
Radiculopathy 56.47 12.74 35 25071 8789 79710493
Beta haemolytic streptococcal infection 52.32 12.74 21 25085 2076 79717206
Product availability issue 51.30 12.74 25 25081 3922 79715360
Application site reaction 51.16 12.74 16 25090 760 79718522
Rheumatoid arthritis 50.52 12.74 4 25102 208466 79510816
Pneumonia streptococcal 50.09 12.74 22 25084 2723 79716559
Product quality issue 49.16 12.74 57 25049 33883 79685399
Chronic obstructive pulmonary disease 46.91 12.74 91 25015 85328 79633954
Application site rash 45.20 12.74 19 25087 2113 79717169
Dyspepsia 44.82 12.74 103 25003 108584 79610698
Drug use disorder 42.33 12.74 29 25077 8622 79710660
Drug withdrawal syndrome 41.64 12.74 53 25053 34665 79684617
Therapeutic product effect incomplete 41.53 12.74 118 24988 141527 79577755
Throat clearing 41.20 12.74 19 25087 2635 79716647
Alcohol interaction 40.81 12.74 23 25083 4851 79714431
Drug intolerance 39.25 12.74 17 25089 264102 79455180
Drug screen positive 38.68 12.74 24 25082 6039 79713243
Application site irritation 38.51 12.74 16 25090 1728 79717554
Nasal obstruction 38.38 12.74 17 25089 2147 79717135
Reversible airways obstruction 38.29 12.74 17 25089 2159 79717123
Premature delivery 36.67 12.74 41 25065 23426 79695856
Application site pain 36.00 12.74 21 25085 4726 79714556
Application site scar 35.86 12.74 9 25097 188 79719094
Withdrawal syndrome 35.42 12.74 43 25063 26811 79692471
Therapeutic product effect decreased 34.96 12.74 5 25101 163858 79555424
Treatment noncompliance 34.11 12.74 60 25046 52208 79667074
Arthropathy 32.27 12.74 8 25098 177103 79542179
Frequent bowel movements 32.16 12.74 43 25063 29496 79689786
Arthralgia 30.67 12.74 86 25020 571717 79147565
Oral candidiasis 30.55 12.74 42 25064 29586 79689696
Anxiety 30.01 12.74 156 24950 248356 79470926
Joint swelling 29.99 12.74 28 25078 288618 79430664
Alopecia 29.74 12.74 18 25088 231337 79487945
Maternal drugs affecting foetus 29.13 12.74 13 25093 1670 79717612
Schizoaffective disorder 29.08 12.74 14 25092 2138 79717144
Euphoric mood 28.89 12.74 22 25084 7704 79711578
Loss of consciousness 28.89 12.74 117 24989 167826 79551456
Infective exacerbation of chronic obstructive airways disease 28.48 12.74 15 25091 2769 79716513
Diarrhoea 27.91 12.74 163 24943 880326 78838956
Reversible cerebral vasoconstriction syndrome 27.16 12.74 15 25091 3042 79716240
Colitis ulcerative 26.82 12.74 43 25063 34699 79684583
Fatigue 26.44 12.74 178 24928 929549 78789733
Dysmetropsia 25.71 12.74 6 25100 91 79719191
Infection 25.63 12.74 23 25083 241689 79477593
Unresponsive to stimuli 25.37 12.74 55 25051 55733 79663549
Sputum purulent 25.22 12.74 11 25095 1338 79717944
Application site urticaria 24.55 12.74 7 25099 241 79719041
Application site vesicles 24.53 12.74 11 25095 1429 79717853
Schizophrenia 24.17 12.74 27 25079 15413 79703869
Tachycardia 23.86 12.74 115 24991 177653 79541629
Renal impairment 23.68 12.74 10 25096 157773 79561509
Systemic lupus erythematosus 23.00 12.74 5 25101 121144 79598138
Mental status changes 22.83 12.74 59 25047 66900 79652382
Nasopharyngitis 22.61 12.74 28 25078 253853 79465429
Body temperature abnormal 22.06 12.74 12 25094 2363 79716919
Pubic pain 21.74 12.74 6 25100 183 79719099
Application site dermatitis 21.59 12.74 6 25100 188 79719094
Disease progression 21.46 12.74 16 25090 184346 79534936
Nightmare 21.34 12.74 33 25073 25828 79693454
Emphysema 21.33 12.74 26 25080 16274 79703008
Hepatic enzyme increased 21.06 12.74 16 25090 182594 79536688
Full blood count abnormal 20.85 12.74 42 25064 40432 79678850
Regurgitation 20.27 12.74 12 25094 2775 79716507
Loss of proprioception 20.06 12.74 8 25098 778 79718504
Foetal distress syndrome 19.83 12.74 7 25099 485 79718797
Application site discolouration 19.32 12.74 8 25098 856 79718426
Tobacco withdrawal symptoms 18.65 12.74 3 25103 4 79719278
Intentional overdose 18.35 12.74 74 25032 105886 79613396
Treatment failure 18.34 12.74 16 25090 170470 79548812
Myocarditis 18.31 12.74 28 25078 21705 79697577
Chest X-ray abnormal 18.20 12.74 17 25089 7866 79711416
Axonal neuropathy 18.03 12.74 10 25096 2044 79717238
Arteriosclerosis coronary artery 17.98 12.74 25 25081 17791 79701491
Impaired healing 17.95 12.74 3 25103 87652 79631630
Vitamin B12 deficiency 17.46 12.74 16 25090 7225 79712057
Poor quality product administered 17.32 12.74 12 25094 3633 79715649
Pulmonary oedema 17.21 12.74 64 25042 88190 79631092
Contusion 17.20 12.74 13 25093 148763 79570519
Derealisation 17.20 12.74 9 25097 1640 79717642
Application site swelling 16.94 12.74 7 25099 746 79718536
Neuropathy peripheral 16.79 12.74 12 25094 141293 79577989
Ischaemic stroke 16.62 12.74 34 25072 33097 79686185
Decreased appetite 16.53 12.74 54 25052 342364 79376918
Hepatocellular injury 16.29 12.74 42 25064 47551 79671731
Suicidal ideation 16.28 12.74 57 25049 76283 79642999
Breathing-related sleep disorder 16.27 12.74 5 25101 224 79719058
Exposure during pregnancy 16.23 12.74 69 25037 101063 79618219
Secondary immunodeficiency 16.20 12.74 11 25095 3223 79716059
Xanthogranuloma 16.20 12.74 4 25102 78 79719204
Chest discomfort 16.19 12.74 86 25020 137958 79581324
Upper-airway cough syndrome 15.87 12.74 19 25087 11674 79707608
Tobacco interaction 15.83 12.74 4 25102 86 79719196
Oropharyngeal discomfort 15.68 12.74 15 25091 7151 79712131
Palpitations 15.62 12.74 80 25026 126530 79592752
Oophoritis 15.61 12.74 4 25102 91 79719191
COVID-19 15.55 12.74 16 25090 157658 79561624
Stomatitis 15.51 12.74 14 25092 146743 79572539
Delirium 15.37 12.74 60 25046 84567 79634715
Nervousness 15.26 12.74 33 25073 33382 79685900
Sinus tachycardia 15.22 12.74 35 25071 36873 79682409
Mobility decreased 15.01 12.74 10 25096 122165 79597117
Wound 14.97 12.74 9 25097 116170 79603112
Musculoskeletal stiffness 14.86 12.74 20 25086 174988 79544294
Peripheral swelling 14.83 12.74 40 25066 269577 79449705
Potentiating drug interaction 14.80 12.74 16 25090 8803 79710479
Irritability 14.80 12.74 37 25069 41107 79678175
Cardiac death 14.75 12.74 8 25098 1566 79717716
False positive investigation result 14.32 12.74 7 25099 1105 79718177
General physical health deterioration 14.28 12.74 42 25064 275196 79444086
Urinary tract infection 14.16 12.74 42 25064 274470 79444812
Maternal exposure during pregnancy 13.98 12.74 82 25024 136456 79582826
Abortion induced 13.91 12.74 14 25092 7095 79712187
Rhinitis 13.79 12.74 20 25086 14787 79704495
Off label use 13.79 12.74 202 24904 907013 78812269
Rectal haemorrhage 13.78 12.74 54 25052 76246 79643036
Plethysmography 13.75 12.74 3 25103 33 79719249
Cardiac arrest 13.71 12.74 97 25009 171999 79547283
Premature labour 13.70 12.74 15 25091 8375 79710907
Antipsychotic drug level decreased 13.68 12.74 7 25099 1217 79718065
Psychotic disorder 13.62 12.74 36 25070 41366 79677916
Swelling 13.61 12.74 30 25076 216681 79502601
White blood cell count decreased 13.60 12.74 24 25082 188264 79531018
Premature separation of placenta 13.57 12.74 7 25099 1239 79718043
Non-small cell lung cancer stage IIIB 13.43 12.74 3 25103 37 79719245
Accidental death 13.42 12.74 11 25095 4280 79715002
Nausea 13.42 12.74 395 24711 956801 78762481
Colitis 13.34 12.74 52 25054 73255 79646027
Glossodynia 13.32 12.74 8 25098 103329 79615953
Psoriatic arthropathy 13.31 12.74 4 25102 77995 79641287
Respiratory arrest 13.17 12.74 44 25062 57506 79661776
Myoclonic epilepsy 13.08 12.74 8 25098 1962 79717320

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
FDA CS M0014836 Nicotine
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018722 Nicotinic Agonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D000077444 Smoking Cessation Agents
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
CHEBI has role CHEBI:22917 botanical insecticides
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:47958 muscarinic agonists
CHEBI has role CHEBI:49110 peripheral nervous system drugs
CHEBI has role CHEBI:50846 Immunologic factor
CHEBI has role CHEBI:50905 teratogeno
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:52290 mitogens
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Nicotine Withdrawal Symptoms indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Acetylcholine-binding protein Unclassified Ki 7.20 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Soluble acetylcholine receptor Unclassified Ki 7.52 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 5 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 7.40 IUPHAR

External reference:

IDSource
4020286 VUID
N0000148163 NUI
D03365 KEGG_DRUG
65-31-6 SECONDARY_CAS_RN
4018610 VANDF
4020286 VANDF
C0028040 UMLSCUI
CHEBI:17688 CHEBI
CHEMBL3 ChEMBL_ID
DB00184 DRUGBANK_ID
D009538 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
2585 IUPHAR_LIGAND_ID
6M3C89ZY6R UNII
1306106 RXNORM
11529 MMSL
5173 MMSL
5174 MMSL
72003 MMSL
d00316 MMSL
001770 NDDF
003575 NDDF
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
77544001 SNOMEDCT_US
D061485 MESH_DESCRIPTOR_UI
NCT PDB_CHEM_ID
CHEMBL3989563 ChEMBL_ID
CHEMBL1201536 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5400 INHALANT 4 mg RESPIRATORY (INHALATION) NDA 29 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotinemint HUMAN OTC DRUG LABEL 1 0113-0206 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0422 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0704 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0713 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0749 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0761 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-1125 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1190 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1352 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7007 LOZENGE 4 mg ORAL ANDA 14 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7008 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7124 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7190 LOZENGE 4 mg ORAL ANDA 15 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7201 LOZENGE 2 mg ORAL ANDA 14 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7203 LOZENGE 4 mg ORAL ANDA 14 sections